IL10 and influenza: However, for every 1-standard deviation fold-increase in the IFNγ:IL-10 ratio (following ex vivo influenza B challenge) from pre- to 4-weeks post-vaccination, the odds of B-LCII decreased by 71% (OR [95% CI]: 0.29 [0.08, 0.76])(Figure 3B); when only PCR-confirmed B-LCII cases were included in the analysis (n = 8), this estimate was very similar (0.186 (0.04, 0.58)).